Rallybio Corporation RLYB on Tuesday shared results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical trial of RLYB116 for complement-mediated diseases, with its initial ...

This Rare Disease Day, observed on Feb. 28 worldwide, the American Kidney Fund is committed to improving the understanding of rare kidney diseases by providing educational resources. An autoimmune ...

Medically reviewed by Michael Menna, DO Complement 3 glomerulopathy is a rare disease caused by a buildup of proteins in the kidneys. The prognosis and life expectancy for C3G depends on the disease ...

"NM-8074 (Ruxoprubart) Sales Forecast"NM-8074 (ruxoprubart) sales market analysis provides in-depth insights into NM-8074 annual sales, market size, and growth forecast across the 7MM through 2034.

Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan reduced proteinuria in patients with rare complement-mediated glomerular diseases vs. placebo.

Recent advances in the understanding of immune-mediated neurological disorders have led to a paradigm shift toward pathophysiology-directed therapies. Central to this progress is a deeper appreciation ...

Neurologic diseases and disorders are now the leading cause of disability nationwide, affecting half the US population. A systematic analysis showed that 1 in 2 people, ie, nearly half the US ...

Danish drugmaker Novo Nordisk has licensed an experimental rare disease drug from biotechnology company Omeros that it sees becoming a differentiating treatment for an array of rare blood and kidney ...

In myasthenia gravis, complement plays a big role in what happens to the muscle end of the neuromuscular junction, explains Miriam Freimer, MD, an author on 5 abstracts presented at the recent 15th ...

When these hormones become imbalanced, it can lead to the development of an endocrine disorder. “An endocrine disorder occurs when your body produces either too much or too little of a particular ...

A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...